| Sep 24 |
Regeneron downgraded at Leerink after Amgen’s court win; Truist defends
|
| Sep 23 |
Regeneron Stock Slides After Court Rejects Injunction Against Eye Drug Biosimilar, Truist Says
|
| Sep 23 |
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
|
| Sep 23 |
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
|
| Sep 23 |
Regeneron falls after judge denies injunction blocking Amgen Eylea biosimilar
|
| Sep 23 |
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
|
| Sep 23 |
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
|
| Sep 20 |
Regeneron/Sanofi Dupixent endorsed in EU for eosinophilic esophagitis for children
|
| Sep 20 |
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
|
| Sep 19 |
The best biotech plays outside the GLP-1 weight-loss market
|
